Literature DB >> 3513813

Gastrointestinal cancer-associated antigen CA 19-9 in histological specimens of pancreatic tumours and pancreatitis.

C Haglund, J Lindgren, P J Roberts, S Nordling.   

Abstract

The expression of the gastrointestinal cancer associated antigen CA 19-9, defined by the monoclonal antibody 1116 NS 19-9, was studied by immunoperoxidase staining in routine formalin-fixed, paraffin-embedded tissue sections from normal pancreata, pancreata with pancreatitis and from benign and malignant pancreatic neoplasms. The formalin-fixed specimens were treated with pepsin, which enhanced the staining intensity. Eighty-five per cent of well to moderately differentiated adenocarcinomas were positive. The staining was most intense in the apical border of cells lining the lumina of malignant glands, and in mucus inside the lumina, but cytoplasmic staining was also seen. In poorly differentiated adenocarcinomas the number of positive cells was smaller and in anaplastic carcinomas only occasional cells were stained. All mucinous cystadenomas and cystadenocarcinomas stained intensely, whereas serous cystadenomas, and all benign and malignant islet cell tumours were negative. Ducts in chronic pancreatitis and in normal pancreata were positive in 96% and 79%, respectively, but the staining was focal and usually weaker than in carcinomas. In acute pancreatitis (92% positive) the staining was more intense, and the CA 19-9 expression was seen predominantly in small terminal ducts and in centroacinar cells. There was an apparent correlation between the degree of differentiation of the ductal adenocarcinomas and the expression of CA 19-9, whereas the correlation between tissue expression and serum levels of CA 19-9 was poor.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3513813      PMCID: PMC2001321          DOI: 10.1038/bjc.1986.34

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  15 in total

1.  Laboratory: The Cultivation of Endameba Gingivalis (Gros) from the Human Mouth.

Authors:  C C Young; C A Kofoid; H G Johnstone
Journal:  Am J Public Health Nations Health       Date:  1929-05

2.  Colorectal carcinoma antigens detected by hybridoma antibodies.

Authors:  H Koprowski; Z Steplewski; K Mitchell; M Herlyn; D Herlyn; P Fuhrer
Journal:  Somatic Cell Genet       Date:  1979-11

3.  Distribution of monoclonal antibody-defined monosialoganglioside in normal and cancerous human tissues: an immunoperoxidase study.

Authors:  J W Arends; C Verstynen; F T Bosman; J Hilgers; Z Steplewski
Journal:  Hybridoma       Date:  1983

4.  Monoclonal antibody detection of a circulating tumor-associated antigen. I. Presence of antigen in sera of patients with colorectal, gastric, and pancreatic carcinoma.

Authors:  M Herlyn; H F Sears; Z Steplewski; H Koprowski
Journal:  J Clin Immunol       Date:  1982-04       Impact factor: 8.317

5.  Radioimmunometric assay for a monoclonal antibody-defined tumor marker, CA 19-9.

Authors:  B C Del Villano; S Brennan; P Brock; C Bucher; V Liu; M McClure; B Rake; S Space; B Westrick; H Schoemaker; V R Zurawski
Journal:  Clin Chem       Date:  1983-03       Impact factor: 8.327

6.  Specific antigen in serum of patients with colon carcinoma.

Authors:  H Koprowski; M Herlyn; Z Steplewski; H F Sears
Journal:  Science       Date:  1981-04-03       Impact factor: 47.728

7.  A monoclonal antibody-defined antigen associated with gastrointestinal cancer is a ganglioside containing sialylated lacto-N-fucopentaose II.

Authors:  J L Magnani; B Nilsson; M Brockhaus; D Zopf; Z Steplewski; H Koprowski; V Ginsburg
Journal:  J Biol Chem       Date:  1982-12-10       Impact factor: 5.157

8.  Gastrointestinal cancer-associated antigen in immunoperoxidase assay.

Authors:  B F Atkinson; C S Ernst; M Herlyn; Z Steplewski; H F Sears; H Koprowski
Journal:  Cancer Res       Date:  1982-11       Impact factor: 12.701

9.  Comparison of CA 19-9 and carcinoembryonic antigen (CEA) levels in the serum of patients with colorectal diseases.

Authors:  P Kuusela; H Jalanko; P Roberts; P Sipponen; J P Mecklin; R Pitkänen; O Mäkelä
Journal:  Br J Cancer       Date:  1984-02       Impact factor: 7.640

10.  Evaluation of CA 19-9 as a serum tumour marker in pancreatic cancer.

Authors:  C Haglund; P J Roberts; P Kuusela; T M Scheinin; O Mäkelä; H Jalanko
Journal:  Br J Cancer       Date:  1986-02       Impact factor: 7.640

View more
  33 in total

Review 1.  Adenocarcinoma cells in effusion cytology as a diagnostic pitfall with potential impact on clinical management: a case report with brief review of immunomarkers.

Authors:  Sinchita Roy Chowdhuri; Patricia Fetsch; Jennifer Squires; Elise Kohn; Armando C Filie
Journal:  Diagn Cytopathol       Date:  2012-11-16       Impact factor: 1.582

2.  Localization of antigen defined by anti-scirrhous gastric carcinoma monoclonal antibody S202 in fixed human cancer tissues.

Authors:  T Yokota; T Takahashi; T Yamaguchi; K Sawai; M Shimotsuma; M Doi; T Masuko; Y Hashimoto
Journal:  Gastroenterol Jpn       Date:  1988-12

Review 3.  Laboratory tests in the diagnosis of the chronic pancreatic diseases. Part 6. Differentiation between chronic pancreatitis and pancreatic cancer.

Authors:  E J Boyd; H Rinderknecht; K G Wormsley
Journal:  Int J Pancreatol       Date:  1988-05

4.  CA 19-9 in pancreatic cancer: retrospective evaluation of patients with suspicion of pancreatic cancer.

Authors:  Victor Molina; Laura Visa; Carles Conill; Salvador Navarro; Jose M Escudero; Jose M Auge; Xavier Filella; Miguel A Lopez-Boado; Joana Ferrer; Laureano Fernandez-Cruz; Rafael Molina
Journal:  Tumour Biol       Date:  2011-12-29

5.  The sTRA Plasma Biomarker: Blinded Validation of Improved Accuracy Over CA19-9 in Pancreatic Cancer Diagnosis.

Authors:  Ben Staal; Ying Liu; Daniel Barnett; Peter Hsueh; Zonglin He; ChongFeng Gao; Katie Partyka; Mark W Hurd; Aatur D Singhi; Richard R Drake; Ying Huang; Anirban Maitra; Randall E Brand; Brian B Haab
Journal:  Clin Cancer Res       Date:  2019-01-07       Impact factor: 12.531

6.  A tumor-associated antigen in the scirrhous gastric carcinoma cell line MK-01 defined by monoclonal antibody S202.

Authors:  T Yokota; T Masuko; T Yamaguchi; K Kitamura; T Takahashi; Y Hashimoto
Journal:  Jpn J Surg       Date:  1989-07

7.  Alpha fetoprotein-producing acinar cell carcinoma of the pancreas showing multiple lines of differentiation.

Authors:  T Shinagawa; M Tadokoro; S Maeyama; C Maeda; S Yamaguchi; T Morohoshi; E Ishikawa
Journal:  Virchows Arch       Date:  1995       Impact factor: 4.064

8.  Biliary CA 19-9 values correlate with the risk of hepatic metastases in patients with adenocarcinoma of the pancreas.

Authors:  R C Montgomery; J P Hoffma; E A Ross; L B Riley; J A Ridge; B L Eisenberg
Journal:  J Gastrointest Surg       Date:  1998 Jan-Feb       Impact factor: 3.452

9.  Pancreatic acinar cell carcinoma. An analysis of cell lineage markers, p53 expression, and Ki-ras mutation.

Authors:  A Hoorens; N R Lemoine; E McLellan; T Morohoshi; T Kamisawa; P U Heitz; B Stamm; J Rüschoff; B Wiedenmann; G Klöppel
Journal:  Am J Pathol       Date:  1993-09       Impact factor: 4.307

10.  Analysis of the Lewisx epitope in human pancreas and pancreatic adenocarcinomas.

Authors:  H P Sinn; S A Brown; E Oberle; J S Thompson
Journal:  Int J Pancreatol       Date:  1992-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.